Condition: NSCLC (Advanced Non-small Cell Lung Cancer) · Sponsor: Hedera Dx SA
The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.
This description comes directly from the study's public registry record.
Dr. Christian Meisel, MD PhD · +41 21 588 16 54 · HederaDxStudies@hederadx.com
Always discuss trial participation with your own doctor first.
| Université de Lorraine | Nancy, Lorraine, France | Recruiting |
| University of Naples "Federico II" | Naples, Italy | Recruiting |
| General Universitario Gregorio Marañon | Madrid, Spain | Not Yet Recruiting |
| Hôpitaux Universitaires Genève | Geneva, Canton of Geneva, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07096258